- HK$20.27bn
- HK$10.47bn
- $630.20m
- 15
- 39
- 35
- 15
REG - Hutchmed China Ltd - Directorate Change
AnnouncementRCS - Hutchmed China Ltd - HUTCHMED Completes Enrollment of Phase III Trial
AnnouncementREG - Hutchmed China Ltd - 2025 Interim Results
AnnouncementREG - Hutchmed China Ltd - HUTCHMED to Announce 2025 Half-Year Results
AnnouncementREG - Hutchmed China Ltd - Update on Joint Corporate Brokers in London
AnnouncementREG - Hutchmed China Ltd - Total Voting Rights
AnnouncementREG - Hutchmed China Ltd - China Approval based on Phase III SACHI Trial
AnnouncementREG - Hutchmed China Ltd - Blocklisting Six Monthly Return
AnnouncementREG - Hutchmed China Ltd - Grant of Share Options and Awards under LTIP
AnnouncementRCS - Hutchmed China Ltd - HUTCHMED and Innovent Announce NDA Acceptance
AnnouncementRCS - Hutchmed China Ltd - HUTCHMED Highlights SACHI Phase III Data at ASCO
AnnouncementREG - Hutchmed China Ltd - Total Voting Rights
AnnouncementRCS - Hutchmed China Ltd - HUTCHMED Highlights Data to be Presented at ASCO
AnnouncementREG - Hutchmed China Ltd - AGM held on May 13, 2025 – Poll Results
AnnouncementRCS - Hutchmed China Ltd - HUTCHMED - Data to be Presented at AACR 2025
AnnouncementRCS - Hutchmed China Ltd - HUTCHMED Completes Enrollment of Phase II Study
AnnouncementREG - Hutchmed China Ltd - 2024 Annual Report and Notice of AGM
AnnouncementREG - Hutchmed China Ltd - Extraordinary General Meeting – Poll Results
AnnouncementRCS - Hutchmed China Ltd - NMPA Conditional Approval for TAZVERIK®
Announcement